Advance Online
Two women wearing sunglasses and smiling outside.
Advance Online

New Dosing Available for SKYRIZI®

SKYRIZI® (risankizumab-rzaa) is now available in the U.S. as a single dose injection for the treatment of adults with moderate-to-severe plaque psoriasis.

On August 9, 2021, AbbVie announced that SKYRIZI® (risankizumab-rzaa), an interleukin-23 inhibitor, is now available in the U.S. as a single dose injection for the treatment of adults with moderate-to-severe plaque psoriasis. The U.S. Food and Drug Administration (FDA) approved SKYRIZI® as a single 150mg dose based on three clinical trials which demonstrated that it was bioequivalent, meaning it worked the same as two 75 mg doses. Following the starter doses, it can be administered via 1 prefilled pen or syringe.[1]

“Risankizumab [has been shown to have] long-term safety and efficacy results. Prior to this FDA approval, patients would have to do 2 injections of drug every time the drug was dosed, which is 4 times per year. Now, following this FDA approval, patients only have to do a single injection for each dose. The bottom line is that this new FDA approval now cuts the required number of risankizumab shots to treat psoriasis in half; patients only have to do 4 shots per year, which makes this drug very convenient to use,” shares Andrew Blauvelt, M.D., dermatologist and President of the Oregon Medical Research Center. Dr. Blauvelt was an investigator in one of the studies that reviewed the efficacy, safety, and usability of this new risankizumab formulation and administration.

With this new announcement, SKYRIZI®is now the only 4-dose-a-year biologic treatment for psoriasis that is available as a single-dose pen or prefilled syringe.[1]

References:

1.       https://www.prnewswire.com/news-releases/skyrizi-risankizumab-rzaa-now-available-in-the-us-as-a-single-150-mg-injection-for-adults-with-moderate-to-severe-plaque-psoriasis-301350489.html?tc=eml_cleartime

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2021 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.